CytomX Therapeutics (CTMX) Total Non-Current Liabilities (2014 - 2026)

CytomX Therapeutics' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $35.0 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 49.47% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.0 million (down 49.47% YoY) and the FY2025 annual result came in at $48.2 million, down 58.75% from the prior year.
• Total Non-Current Liabilities was $35.0 million for Q1 2026 at CytomX Therapeutics, down from $48.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $346.6 million in Q4 2022 and bottomed at $35.0 million in Q1 2026.
• A 5-year average of $171.0 million and a median of $172.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities fell 6.56% — and 2025, when it sank 72.7%.
• CytomX Therapeutics' Total Non-Current Liabilities stood at $346.6 million in 2022, then slipped by 29.22% to $245.3 million in 2023, then slumped by 52.36% to $116.9 million in 2024, then sank by 58.75% to $48.2 million in 2025, then slipped by 27.39% to $35.0 million in 2026.
• Business Quant data shows CTMX's Total Non-Current Liabilities at $35.0 million in Q1 2026, $48.2 million in Q4 2025, and $46.6 million in Q3 2025.